Global /Japan /Healthcare /Biotechnology /7096

StemCell Institute Inc.

7096

• TSE: 7096 • Delayed

746JPY -0.8%

4.66 USD

As of 6 June 2026, StemCell Institute Inc. has a market cap of $48.15M USD, ranking #30862 globally and #2879 in Japan. It ranks #2788 in the Healthcare sector, and #539 in the Biotechnology industry.

Global Rank

30862

Country Rank

2879

Sector Rank

2788

Industry Rank

539

Key Stats

Market Cap

$48.15MUSD

7.71B JPY

Enterprise Value

$34.49MUSD

5.52B JPY

Revenue (TTM)

$17.39MUSD

2.78B JPY

EBITDA (TTM)

$2.58MUSD

413.0M JPY

Net Income (TTM)

$1.2MUSD

192.0M JPY

EBITDA Margin

15%

Profit Margin

6.9%

PE Ratio

39.7

Forward PE

38.8

PS Ratio

2.8

PB Ratio

2.5

EV/EBITDA

13.4

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Biotechnology

CEO

Takafumi Shimizu open_in_new

Employees

117

Founded

1999

Website

stemcell.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.8%	-3.6%	-8.8%	-9.4%	-13%	-5.7%	-42%	-65%	-72%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	7096 株式会社ステムセル研究所 ISIN: JP3399640006 Shares Out.: Shares Outstanding: 10.07M¹ Shares Float: 2.318M² TV: TradingView: TSE: 7096 SA: Stock Analysis: TYO: 7096 YF: Yahoo Finance: 7096.T GF: Google Finance: TYO: 7096 BA: Barron's: 7096 MS: Morningstar: XTKS: 7096	746 JPY	TV: TradingView: TSE: 7096 SA: Stock Analysis: TYO: 7096 YF: Yahoo Finance: 7096.T GF: Google Finance: TYO: 7096 BA: Barron's: 7096 MS: Morningstar: XTKS: 7096

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About StemCell Institute Inc.

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of new cell-based treatments, and pharmaceuticals and medical devices. It also engages in cell contract management and transportation business; extraction, purification, processing, storage, testing and sales of biological tissue-derived components; and medical facility operation and management business. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.

Similar Companies

Industry: Biotechnology (Japan)

Name	Market Cap (USD) diff.	PE	Country
GNI Group Ltd. TSE: 2160	$1.02B 162.8B JPY 2K%	-	Japan
PeptiDream Inc. TSE: 4587	$929.38M 148.73B JPY 2K%	-	Japan
Oncolys BioPharma Inc. TSE: 4588	$526.3M 84.22B JPY 993%	-	Japan
Cuorips Inc. TSE: 4894	$349.85M 55.99B JPY 627%	-	Japan
Innovacell Inc. TSE: 504A	$169.94M 27.19B JPY 253%	-	Japan
Stella Pharma Corp. TSE: 4888	$113.62M 18.18B JPY 136%	-	Japan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 379K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 332K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 100K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 92K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 89K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 89K%	37.2	Switzerland

chevron_leftBack